Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +5.26% and -70.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for ...

Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...

Recursion announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $162.3 million in its third quarter. The Salt Lake City-based company said it had a ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.

Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Social media users took the "Scream" trailer to task in the wake of Barrera's removal following pro-Palestinian posts ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...